The Times

.

Immuno Cure secured maximum subsidy from HKSTP

  • Written by Auzzi Shopping

Significant funding support for HIV Vaccine Clinical Trial

HONG KONG SAR - Media OutReach - 17 October 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today that Hong Kong Science and Technology Parks Corporation (“HKSTP”) has awarded maximum amount of HK$8 million matching funding to Immuno Cure under the Clinical Translational Catalyst program (“CTC Program”) for conducting the Phase 1 Clinical Trial of ICVAX, a therapeutic vaccine against HIV/AIDS.


Notice: Undefined offset: 1 in /httpdocs/templates/gk_university/html/pagination.php on line 18

Notice: Undefined offset: 1 in /httpdocs/templates/gk_university/html/pagination.php on line 34

Notice: Undefined offset: 2 in /httpdocs/templates/gk_university/html/pagination.php on line 34

Notice: Undefined offset: 3 in /httpdocs/templates/gk_university/html/pagination.php on line 34
hacklink hack forum hacklink film izle hacklink makrobetperabetgamdomเว็บสล็อตเว็บสล็อตสล็อตเว็บตรงเว็บบาคาร่าสล็อตเว็บตรงRoyal Reels pokiesRoyal Reels reviewRoyal Reels reviewRoyal Reels bonusHitbet bahisสล็อตPadişahbetcasibomGalabetGalabetRoyal ReelsRoyal reelsVipparkPadişahbetPadişahbetsafirbetimajbetcasibomiptv satın aliptv satın alvdcasinovdcasino girişzlibraryzlibraryzlibrarybetparkmatbetjojobetjojobetmatbetlunabetnakitbahiscasibomholiganbet